A new globally leading centre for infectious diseases research, education and public health will be built in Melbourne to support the Australian Institute for Infectious Disease (AIID). Providing state-of-the-art research platforms and technology will enable research translation into faster, more effective diagnostic tests, treatments, vaccines, and public health interventions for infectious diseases.
Learn more about the AIID facility from our leaders in this video:
With government funding secured, a strong business case finalised and land identified, the AIID project is well underway.
Leading Melbourne architectural firm, Wardle has been announced as the lead architects and Aurecon is the lead engineering firm.
Concept design for the building was completed in early 2023 with input and collaboration from Foundation Partner researchers and staff, who will ultimately be the future users of the building’s cutting-edge facilities.
The detailed schematic design process is currently underway and due for completion in late 2023. A town planning application will soon be submitted to the City of Melbourne as well.
Early works are scheduled to commence in 2024.
Images of the building design can be seen below:
The Victorian Government has committed up to $400 million for the $650 million project, with funding also being provided by the University of Melbourne, the Doherty Institute and Burnet Institute, along with philanthropic support.
The new facility will be built in the world-leading Melbourne Biomedical Precinct adjacent to the existing Doherty Institute building on Elizabeth Street. It will enable the University of Melbourne and Doherty Institute to expand and the Burnet Institute to relocate to the Parkville site. The facility will house more than 1000 scientists, academics, students and public health experts from the institutes alongside industry partners. Co-location will strengthen collaboration and engagement with their peers nationally and internationally and create a platform for new partnerships to be forged with the private sector and industry stakeholders.
The AIID will provide vital facilities and research platforms needed to develop vaccines and treatments for infectious diseases, including: